Pulmonology — Small Airway Obstructive Diseases
Bronchiolitis obliterans
Bronchiolitis obliterans, also referred to as obliterans bronchiolitis syndrome (OBS) in the post-transplant context, is a rare chronic lung disease characterized by progressive inflammation and fibrosis of the bronchioles, the smallest airways in the bronchial tree located downstream from the segmental bronchi. This fibrotic process leads to partial or complete obstruction of the bronchiolar lumen, irreversibly reducing ventilation to the corresponding alveolar territories. In contrast to acute infectious bronchiolitis in infants, which is a benign and transient condition, adult obliterans bronchiolitis is a severe, often progressive, and poorly reversible disease. It is the main long-term chronic pulmonary complication after bone marrow or hematopoietic stem cell transplantation, where it represents the pulmonary manifestation of chronic graft-versus-host disease (GVHD). It can also occur after lung transplantation, severe respiratory infection, inhalation of toxic substances, or in the context of autoimmune diseases. Diagnosis is often delayed due to the non-specificity of initial symptoms, which are dominated by progressive exertional dyspnea and chronic cough. The absence of an established curative treatment makes prevention and early detection particularly important.
Acute respiratory decompensation
In a person with known bronchiolitis obliterans, any rapid worsening of dyspnea, severe resting hypoxemia, cyanosis, tachycardia, or altered consciousness may indicate acute respiratory decompensation, severe bronchial superinfection, or spontaneous pneumothorax on a hyperinflated lung. These situations require immediate emergency hospital management.
Call 911 immediately.
Pathophysiology
Bronchiolitis obliterans results from an assault on the bronchiolar epithelial cells followed by an aberrant repair response leading to endo- and peribronchiolar fibrosis. Two distinct lesion mechanisms can be observed depending on the cause and stage of development.
| Mechanism | Histological description | Associated clinical context |
|---|---|---|
| Constrictive obliterative bronchiolitis (scarring) | Progressive concentric submucosal and peribronchiolar fibrosis narrowing the bronchiolar lumen from the outside; residual lumen often eccentric; partially preserved bronchiolar architecture | The dominant form in post-bone marrow transplant secondary bacterial infection, autoimmune diseases (rheumatoid arthritis, Sjögren's syndrome), toxic inhalations, and infectious sequelae. |
| Bronchiolitis obliterans with organizing pneumonia (BOOP/PO) | Endoluminal fibroblastic buds (Masson bodies) obstructing bronchioles and adjacent alveoli; associated peripheral inflammation; potentially reversible process with corticosteroids | Cryptogenic organizing pneumonia (formerly idiopathic BOOP), organizing pneumonia secondary to infection, drug toxicity, or collagenosis |
ℹ️
Organizing pneumonia (OP, formerly BOOP) and constrictive obliterative bronchiolitis are two histologically and clinically distinct entities, although often confused. OP is generally sensitive to corticosteroids and reversible, whereas constrictive obliterative bronchiolitis is poorly reversible and responds poorly to corticosteroids. This distinction is essential as it directly determines therapeutic options and prognosis.
Causes and associated conditions
| Category | Causes and contexts |
|---|---|
| Post-hematopoietic stem cell transplant (HSCT) | Pulmonary manifestation of chronic GvT; occurs in 6 to 26% of allogeneic transplants; the leading cause of non-relapse-related mortality following HSCT; typically begins between 6 months and 3 years post-transplant |
| Post-lung transplant | The most common and most feared chronic complication following lung transplantation; affects 50 to 60% of lung transplant recipients at 5 years; the leading cause of late mortality after lung transplantation; reflects chronic cellular and humoral rejection |
| Severe respiratory infections | Sequelae of severe viral infections: adenovirus (particularly serotypes 3, 7, 21), measles virus, severe respiratory syncytial virus (RSV), mycoplasma., Influenza ; Common pediatric conditions following severe infantile viral bronchiolitis |
| Toxic inhalations | Sulfur dioxide, chlorine, ammonia, nitrogen oxides, industrial fumes, diacetyl (artificial butter flavoring: popcorn lung); occurs after acute intense exposure or chronic low-dose exposure |
| Autoimmune diseases and connectivites | Rheumatoid arthritis (most common autoimmune cause), Sjögren's syndrome, systemic sclerosis, systemic lupus erythematosus, polymyositis-dermatomyositis |
| Drugs and toxic substances | Penicillamine, gold salts, amiodarone, bleomycin, busulfan, certain anticonvulsants; drug-induced lung toxicity should always be considered in the presence of any unexplained bronchiolar disease. |
| Idiopathic | No cause identified despite exhaustive workup; diagnosis of exclusion; represents a minority fraction of cases |
Clinical manifestations
The clinical presentation of bronchiolitis obliterans is dominated by insidious progressive dyspnea, often dismissed as unimportant at the beginning of its course, delaying diagnosis by several months to several years in some cases.
| Symptom or sign | Clinical characteristics |
|---|---|
| Progressive exertional dyspnea | A cardinal sign, present in more than 95% of cases; initially occurring during intense exertion, then during moderate exertion, and finally at rest in advanced stages; the progression is generally slow, taking months to years |
| Chronic cough | Dry or non-productive, persistent cough; worsens with intercurrent respiratory infections; rarely primary but almost always present |
| Wheezing and crackles | Wheezing, sometimes audible at a distance, indicating diffuse bronchiolar obstruction; often confused with asthma, especially in a pediatric context. |
| Reduced exercise tolerance | Progressive limitation of daily physical activities; fatigue on exertion disproportionate to the clinical appearance at rest |
| Pulmonary auscultation | Diffuse expiratory wheezes, sometimes late crackles in forms with a fibrous component; auscultatory silence in areas of severe air trapping. |
| Signs of advanced decompensation | Digital clubbing, cyanosis of the extremities, signs of chronic cor pulmonale (secondary pulmonary hypertension) in very advanced forms |
| Recurrent respiratory infections | Frequent bronchial superinfections favored by the stasis of secretions in poorly ventilated areas; each infectious episode can accelerate the progression of bronchiolar fibrosis. |
Diagnosis
The diagnosis of bronchiolitis obliterans is a multimodal process combining clinical, functional, radiological, and, if necessary, histological data. There is no single diagnostic test.
- Spirometry with flow-volume curve: characteristic obstructive pattern with reduced FEV1, FEV1/FVC ratio, and functional residual capacity (FRC); reversibility with bronchodilators is absent or minimal, distinguishing bronchiolitis obliterans from asthma; FVC may be reduced in severe forms.
- Body plethysmography: increased residual volume (RV) and RV/TLC ratio, indicative of chronic air trapping.
- Diffusing capacity of the lung for carbon monoxide (DLCO): often reduced, reflecting distal alveolar-capillary damage
- High-resolution thoracic CT scan during inspiration and expiration: reference morphological examination; highlights mosaic air trapping on expiration (hypodense areas persisting on expiration), bronchial wall thickening, traction bronchiectasis, and ground-glass opacity in areas of active inflammation; mosaic air trapping on expiration is the most suggestive CT sign.
- Six-minute walk test with oximetry: functional assessment of exercise tolerance and exercise desaturation; important longitudinal monitoring parameter
- Bronchoalveolar lavage (BAL) via fiberoptic bronchoscopy: cellular profile varies according to the cause; alveolar neutrophilia in post-transplant and post-infectious forms; lymphocytosis in autoimmune and drug-induced forms; allows for the exclusion of opportunistic infection in immunocompromised patients.
- VATS (Video-Assisted Thoracoscopic Surgery) pulmonary biopsy: reference examination for histological confirmation when diagnosis remains uncertain despite non-invasive workup; highlights characteristic concentric submucosal fibrosis and partial or total bronchiolar obliteration
- Transbronchial biopsy during bronchoscopy: insufficient sensitivity for constrictive obliterative bronchiolitis (less than 30% %) due to the focal distribution of lesions; more useful for organized pneumonia
- Etiological assessment: search for the underlying cause according to the clinical context (anti-nuclear antibodies, RF, anti-CCP antibodies, ANCA, dosage of suspected drugs, viral serologies)
ℹ️
In the post-hematopoietic stem cell transplant setting, bronchiolitis obliterans syndrome (BOS) is defined by clinical and functional criteria standardized by the National Institutes of Health (NIH): FEV1/FVC < 0.7 AND FEV1 < 75% of the predicted value, in the absence of active respiratory infection, with or without histological confirmation. This diagnosis can therefore be made without a lung biopsy in this specific context.
Differential diagnosis
| Affection | Distinguishing elements |
|---|---|
| Asthma | Reversible airflow obstruction, VEMS variability, bronchial hyperresponsiveness, absence of fixed air trapping on CT scan, response to inhaled corticosteroids |
| COPD (emphysema, chronic bronchitis) | Major smoking history, emphysematous destruction on CT scan, chronic bronchial hypersecretion, absence of post-transplant or autoimmune context. |
| Bronchiolitis obliterans organizing pneumonia (BOOP) | Peripheral and peribronchial alveolar infiltrates on CT scan, usually corticosteroid-sensitive, with endoluminal Masson bodies on histology and no concentric submucosal fibrosis. |
| Idiopathic pulmonary fibrosis (IPF) | Predominant restrictive spirometry profile, basilar-posterior honeycombing on CT, UIP pattern on histology, absence of obstruction and air trapping |
| Bronchiectasis | Bronchial dilatation visible on CT scan, daily purulent expectorations, documented chronic bacterial colonization |
| Alpha-1 antitrypsin deficiency | Panlobular emphysema predominantly in the bases, low serum alpha-1-antitrypsin levels, Pi ZZ phenotype or heterozygote |
Therapeutic support
To date, there is no proven curative treatment for constrictive bronchiolitis. Management aims to stabilize the disease, prevent infectious complications, and preserve quality of life.
| Intervention | Modalities and Objectives |
|---|---|
| Systemic corticosteroids | Prednisone 0.5 to 1 mg/kg per day during the active phase; limited efficacy in established fibrotic constrictive forms; better response in early forms and in associated organizing pneumonia; gradual tapering to limit long-term side effects. |
| Azithromycin (anti-inflammatory treatment) | 250 mg three times a week over a long period; anti-inflammatory and immunomodulatory properties independent of antibiotic effect; slows functional progression in post-transplant forms according to several studies; treatment now integrated into post-transplant BOS protocols |
| Inhaled bronchodilators | Long-acting beta-2 agonists and long-acting anticholinergics to improve expiratory flow and relieve dyspnea; moderate symptomatic efficacy in fixed obstructive forms; improvement in exercise tolerance. |
| Post-transplant immunosuppression adjustment | Optimization of immunosuppressive treatment in post-hematopoietic stem cell transplant or lung transplant forms: addition or increase of calcineurin inhibitors, mycophenolate mofetil, everolimus or sirolimus depending on the context; multidisciplinary decision at the transplant center |
| Systemic chronic GVHD treatment | Extracorporeal photopheresis, rituximab, imatinib, ruxolitinib in severe forms of chronic GVHD with SOS refractory to conventional treatments; in a specialized center |
| Respiratory physiotherapy | Bronchial drainage techniques to mobilize stagnant secretions, prevent superinfections, and improve ventilation of obstructed areas; oscillating devices (Flutter, Acapella) as tolerated |
| Respiratory rehabilitation | Structured exercise training program adapted to functional level; improves exercise capacity, reduces perceived dyspnea, and improves quality of life independently of spirometric improvement |
| Long-term oxygen therapy | Indicated in cases of documented resting hypoxemia (SpO2 < 88% at rest or during exercise); improves survival and reduces secondary pulmonary hypertension in advanced forms |
| Vaccination | Systematic annual influenza and pneumococcal vaccination to reduce the risk of infectious exacerbations, particularly in immunocompromised patients. |
| Lung transplantation | Last resort option in forms of terminal respiratory failure refractory to all medical treatment, in the absence of contraindication; multidisciplinary decision in a transplant center |
Long-term surveillance and monitoring
- Spirometry every 3 months during the unstable phase or at the start of treatment, then every 6 months during the stabilization phase; a decrease in FEV1 of more than 10% from the baseline value on two consecutive measurements indicates significant disease progression requiring a reassessment of treatment
- Six-minute walk test with pulse oximetry at each assessment to document exercise tolerance and adapt oxygen therapy if needed
- High-resolution thoracic CT scan for control in case of significant functional deterioration or suspicion of complication (pneumothorax, severe superinfection, new lesion)
- Microbiological surveillance: sputum cultures at each exacerbation to identify colonizing agents and guide antibiotic therapy, with particular attention to opportunistic pathogens in immunocompromised patients
- Screening and treatment of aggravating comorbidities: gastroesophageal reflux disease (recognized progression factor in post-lung transplant forms), pulmonary hypertension, malnutrition, corticosteroid-induced osteoporosis
- Coordinated multidisciplinary follow-up between pulmonology, internal medicine, transplant team, and family physician, depending on the etiological context.
Consult at Clinique Omicron
In cases of progressive exertional dyspnea, chronic cough resistant to usual treatments, or unexplained decrease in exercise tolerance, particularly in the context of a transplant history, autoimmune disease, or toxic exposure, physicians and Nurse Practitioners (NPs) at Clinique Omicron can initiate respiratory functional assessment and refer to pulmonology for further investigation. Coordinated follow-up for chronic respiratory diseases is provided at several Clinique Omicron locations throughout Quebec. Book your appointment online or by phone at one of Clinique Omicron's branches, whether on the South Shore, in Montreal, or in another serviced region in Quebec.
The content of this page is provided for informational purposes only and is not intended to replace the advice of a qualified healthcare professional. Consult a physician for any symptoms, questions or decisions you may have regarding your health.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.